<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486082</url>
  </required_header>
  <id_info>
    <org_study_id>HP02</org_study_id>
    <nct_id>NCT01486082</nct_id>
  </id_info>
  <brief_title>Antimicrobial Susceptibility for Helicobacter Pylori Eradication</brief_title>
  <official_title>Usefulness of Antimicrobial Susceptibility in the Eradication of Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Donostia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Donostia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the high rate of resistance to clarithromycin in our area the investigators proposed
      an study to assess the need of antibiogram previous to the empirical OCA 10 treatment, in
      order to improve the rate of eradication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori

      PURPOSE

      Background:

        -  The rate of eradication of Helicobacter pylori with standard triple therapy (OCA:
           omeprazole + clarithromycin + amoxicillin) in our area is less than the expected
           according to the III Maastricht III consensus. However, the current guidelines recommend
           the use of this therapy.

        -  According to the Maastricht III consensus, in populations with high rates of
           clarithromycin resistance (15-20%) another therapy should be considered, or
           alternatively, testing antimicrobial susceptibility of the H. pylori prior to treatment.

      Objectives:

        -  To clarify the real rate of eradication with OCA therapy with and without antimicrobial
           susceptibility in our area (with high rate of resistance to clarythromycin).

        -  To study which is the diagnostic-therapeutic strategy more cost-effective for the
           treatment of H. pylori.

      Design:

        -  Participants will be screened with a full medical history.

        -  Participants will aleatory receive OCA therapy empirically, or after antimicrobial
           susceptibility test if there is no resistance to clarythromycin, for ten days.

        -  In all cases the eradication of H. pylori will be checked by 13C urea breath test (UBT)
           in 8 weeks after the therapy have been finished.

        -  All the adverse event of the therapy will be reported.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients in whom Helicobacter pylori was eradicated.</measure>
    <time_frame>9 months</time_frame>
    <description>The investigators will measure the rate of eradication in each gruop after OCA treatment. One group receive OCA without antibiogram and the other one after checking the sensitivity to clarithromycin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patient with adverse event</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of the eradication of Helicobacter Pylori in each group.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Empirical OCA</arm_group_label>
    <description>This group will be treated with omeprazole, amoxicillin and clarithromycin without having a previous antibiogram.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCA after antibiogram</arm_group_label>
    <description>This group will be treated with omeprazole, clarithromycin and amoxicillin after an antibiotic susceptibility confirmation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OCA 10</intervention_name>
    <description>A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.</description>
    <arm_group_label>Empirical OCA</arm_group_label>
    <arm_group_label>OCA after antibiogram</arm_group_label>
    <other_name>O: Omeprazole</other_name>
    <other_name>C: Clarithromycin</other_name>
    <other_name>A: Amoxicillin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators recruited patients who are diagnosed with helicobacter pylori infection
        in our hospital (Hospital Donostia) or in any of the specialist care centres under the
        management of the Hospital Donostia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of H. pylori infection provided by culture, histology or UBT.

          -  Patients need and indication to treat (peptic ulcer disease, firs-degree family
             history of gastric cancer, MALT lymphoma or dyspeptic symptoms)

          -  Patients must be 18 years or older.

        Exclusion criteria:

          -  Previous treatment for H. pylori eradication.

          -  Patients who have severe concomitant disease.

          -  Patients who have previous gastric surgery.

          -  Patients who have intolerance to any antimicrobial drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LUIS BUJANDA</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_contact>
    <last_name>LUIS BUJANDA, Dr.</last_name>
    <phone>943 00 7173</phone>
    <email>luis.bujandafernandezdepierola@osakidetza.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUIS BUJANDA, Dr</last_name>
      <phone>943 007173</phone>
      <email>luis.bujandafernandezdepierola@osakidetza.net</email>
    </contact>
    <contact_backup>
      <last_name>MAIDER MARTOS, Dr.</last_name>
      <phone>943 00 7173</phone>
      <email>maider.martosmartin@osakidetza.net</email>
    </contact_backup>
    <investigator>
      <last_name>LUIS BUJANDA, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>December 11, 2011</last_update_submitted>
  <last_update_submitted_qc>December 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Donostia</investigator_affiliation>
    <investigator_full_name>LUIS BUJANDA</investigator_full_name>
    <investigator_title>Director, Head of Gastroenterology Department, principal investigator, clinical proffesor</investigator_title>
  </responsible_party>
  <keyword>OCA 10</keyword>
  <keyword>Antibiogram</keyword>
  <keyword>Eradication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

